GRP
TVRD

Global Retirement Partners’s Tvardi Therapeutics TVRD Stock Holding History

Global Retirement Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$75 – 3489
2023
Q3 		$75 Hold
1
– – ﹤0.01% 3186
2023
Q2 		$147 Hold
1
– – ﹤0.01% 3117
2023
Q1 		$219 Hold
1
– – ﹤0.01% 3076
2022
Q4 		$558 Hold
1
– – ﹤0.01% 2739
2022
Q3 		$0 Buy
+1
New +$362 ﹤0.01% 3030

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Global Retirement Partners's TVRD Position: Q4 2023 in Review

Global Retirement Partners sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 1 share — an estimated $75 sold.

Global Retirement Partners first reported a position in TVRD in Q3 2022 and held it in 5 quarters. The position peaked at $558 in Q4 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Global Retirement Partners reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Global Retirement Partners sold 1 Tvardi Therapeutics share in Q4 2023, an estimated $75.
  • Global Retirement Partners first reported a position in Tvardi Therapeutics in Q3 2022 and held it in 5 quarters.
  • Global Retirement Partners's Tvardi Therapeutics position peaked at $558 in Q4 2022.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Global Retirement Partners's 13F filing for Q4 2023, filed 18 Jan 2024.